Search the Newsreel

Is Johnson & Johnson Stock a Buy After Its $2 Billion TREMFYA Quarter?

Zacks Investment Ideas feature highlights: General Motors, Abbott Laboratories and Johnson & Johnson

For Immediate Release Chicago, IL – July 27, 2026 – Today, Zacks Investment Ideas feature highlights General Motors GM, Abbott Laboratories ABT and Johnson & Johnson JNJ. Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher The 2026 Q2 earnings season will continue at …

Johnson & Johnson Now Leads Its Pitch With An Oncology Bet

Johnson & Johnson (JNJ) has shifted its core strategy from broad diversification to a concentrated bet on oncology, aiming to be the number one oncology company by 2030 with over $50 billion in sales. While the company's overall revenue growth remains strong, its net …

Johnson & Johnson: Quartalszahlen liefern weiterhin Rückhalt für die Aktie

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Dividend Kings are companies that have increased their dividends for 50 or more years in a row. If you're thinking of investing in one, you might be considering AbbVie (NYSE: ABBV) or Johnson & Johnson (NYSE: JNJ) stock. There are good reasons to invest …

Insider trades: Johnson & Johnson, TSMC among notable names (AA:NYSE)

This article highlights recent insider trading activities from July 20 to July 24, 2026. Notable transactions include a sale of 23,054 shares by Johnson & Johnson's Executive Vice President Vanessa Broadhurst. Other companies mentioned in the context of insider trades are Snap and TSMC.

Photos: First look at J&J’s Ottava surgical robot

Johnson & Johnson MedTech has unveiled its Ottava surgical robot, which recently received FDA de novo authorization. This system is the world's first table-integrated, soft-tissue robotics platform, designed to save space in operating rooms by having its four robotic arms emerge from underneath the …

Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened Next

Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer's top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson …

Johnson & Johnson (JNJ) Reports Early Phase 3 Win In Multiple Myeloma

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + …

JNJ|Johnson & Johnson|Kurs:260.350|Änderung %:-1.720

JNJ|Johnson & Johnson|Kurs:263.400|Änderung %:+4.150

Q2 Earnings: Guidance Upgrades Push These 3 Stocks Higher

The 2026 Q2 earnings season will continue at a rapid pace in the coming weeks, with many notable companies on the reporting docket. The big banks helped kick the period off positively, though post-earnings reactions haven't been great for all that have reported. But …

FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson's OTTAVA Robotic Surgical System, marking the regulatory clearance of the world's …

Johnson & Johnson $JNJ Shares Purchased by Orleans Capital Management Corp LA

Orleans Capital Management Corp LA significantly increased its holdings in Johnson & Johnson (JNJ) by 325.4% in the first quarter, bringing its total to 6,376 shares valued at $1.56 million. This comes as J&J reported strong quarterly results, exceeding analyst expectations for both earnings …

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Three analysts have issued bullish sentiments on healthcare companies Johnson & Johnson (JNJ), Helus Pharma (HELP), and Nektar Therapeutics (NKTR). RBC Capital maintained a Buy rating on JNJ with a $287 price target, Bloom Burton maintained a Buy on HELP with a $47 price …

Massive Awards in J&J Mesothelioma Talc Lawsuits as New Cases are Filed

Mesothelioma lawsuits against Johnson & Johnson regarding asbestos contamination in its talcum powder continue to result in significant verdicts, even as new cases are filed. These lawsuits claim that J&J knew about the risks of asbestos in its talc but failed to warn consumers, …

ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook

Medtech giant Johnson & Johnson JNJ reported better-than-expected second-quarter 2026 results, surpassing Wall Street estimates on both the top and bottom lines. The quarterly performance was primarily driven by strong growth in the immunology drug Tremfya and cancer blockbuster Darzalex. Despite reporting such an …

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the …

FDA clears Johnson & Johnson’s surgical robot for ‘the next era in surgery’

The FDA has approved Johnson & Johnson's Ottava Robotic Surgical System for several soft tissue surgeries, enabling J&J to compete with established players like Intuitive Surgical and Medtronic. J&J plans a limited commercial launch in the U.S. initially, focusing on customer success before expanding …

Johnson & Johnson $JNJ Stake Lessened by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its stake in Johnson & Johnson by 3.9% in the first quarter, selling over 232,000 shares. Despite this, J&J accounts for a significant portion of PNC's portfolio, valued at over $1.41 billion. The pharmaceutical giant recently received FDA …

Should FDA’s De Novo Nod for OTTAVA Robotic System Require Action From Johnson & Johnson (JNJ) Investors?

Earlier this week, Johnson & Johnson announced that the FDA had granted De Novo authorization for its OTTAVA Robotic Surgical System, a table‑integrated soft tissue platform cleared for a range of general surgery procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy and appendectomy. This authorization …

US Judge Casts Doubt on 69,000 Cases Alleging J&J Talc Caused Cancer

A federal judge has questioned the validity of approximately 69,000 lawsuits claiming Johnson & Johnson's talc products caused ovarian cancer, demanding plaintiffs provide more specific evidence. U.S. Magistrate Judge Rukhsanah Singh expressed doubt after expert testimony indicated an inability to definitively link talcum powder …

Why is Johnson & Johnson stock climbing today? By Investing.com

Johnson & Johnson Stock (JNJ) Rises as Robotic Surgery Device Is Approved

Johnson & Johnson's stock rose following FDA approval of its Ottava robotic surgical system. This approval allows the company to enter the soft-tissue robotic surgery market, competing with Intuitive Surgical and Medtronic. The Ottava system, designed to save space, is now set for a …

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this world's …

J&J enters US robotic surgery market after device gets marketing authorization

By Puyaan Singh July 22 (Reuters) - Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery ‌device, as the healthcare conglomerate enters the soft-tissue robotic surgery market. The decision ‌marks a key step …

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Johnson & Johnson has announced that its OTTAVA™ Robotic Surgical System has received De Novo authorization from the U.S. FDA, making it the world’s first table-integrated soft tissue robotic system. The system is authorized for a variety of general surgery procedures and aims to …

J&J Receives FDA Approval for Soft Tissue Surgical Robot

Johnson & Johnson has received its first US regulatory authorization from the FDA for its Ottava robotic device, designed for soft tissue surgery. This approval allows J&J to enter the rapidly expanding surgical robotics market, marking the culmination of over a decade of research …

Johnson & Johnson Stock: Q2 2026 Financials Deep Dive

Johnson & Johnson EVP Broadhurst sells $5.79m in stock

Vanessa Broadhurst, EVP of Global Corporate Affairs at Johnson & Johnson, sold 23,054 shares of company stock for approximately $5.79 million. Simultaneously, she acquired the same number of shares through the exercise of employee stock options totaling $3.01 million. These transactions have resulted in …

Johnson & Johnson (JNJ) Raised Its Dividend, Where Does Fair Value Sit?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (JNJ) has declared a third quarter 2026 cash dividend of $1.34 per share, providing income focused investors with fresh information on the …

Johnson & Johnson (JNJ) Stock Looks Fairly Valued With Cash Flow Upside

Johnson & Johnson (JNJ) stock shows a mixed valuation picture, with a discounted cash flow (DCF) model suggesting it is 34.1% undervalued, while its P/E ratio indicates fair valuation close to its modeled fair P/E and slightly above industry average. The company's future growth …

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

DelveInsight Business Research LLP The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies …

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson (JNJ) and Abbott Laboratories (ABT) are moving in opposite strategic directions, with JNJ focusing on pruning its portfolio by spinning off Orthopaedics, while ABT is expanding through its $21 billion Exact Sciences acquisition. JNJ's oncology segment shows strong momentum, while Abbott's …

MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth

The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership …

The Zacks Analyst Blog Highlights Johnson & Johnson, Lam Research, Seagate, KVH Industries and Dawson Geophysical

The Zacks Analyst Blog features research reports on 16 major stocks, including Johnson & Johnson, Lam Research Corp., and Seagate Technology Holdings plc, along with micro-caps KVH Industries, Inc. and Dawson Geophysical Co. The reports highlight company performance, growth drivers, and potential headwinds, with …